Correia Guedes, LeonorReimão, SofiaPaulino, PatríciaNunes, Rita G.Bouça-Machado, RaquelAbreu, DaisyGonçalves, NilzaSoares, TiagoFabbri, MargheritaGodinho, CatarinaPita Lobo, PatríciaNeutel, DulceQuadri, MarialuisaCoelho, MiguelRosa, Mário MiguelCampos, JorgeOuteiro, TiagoSampaio, CristinaBonifati, VincenzoFerreira, Joaquim J2022-09-082022-09-082017Mov Disord. 2017 Sep;32(9):1331-13330885-3185http://hdl.handle.net/10451/54389© John Wiley & Sons, Inc. All rights reserved.Specific T-weighted MRI sequences are able to detect SN neuromelanin (NM) signal changes and accurately discriminate Parkinson’s disease (PD) patients from controls. The study of NM-MRI in PD patients carrying a LRRK2 gene mutation (LRRK2-PD) could contribute to further uncover LRRK2-associated phenotype. Albeit considered to largely overlap idiopathic PD (iPD), differences have been described. Furthermore, the identification of a biomarker of neurodegeneration in LRRK2-PD can eventually support studies in asymptomatic carriers. Castellanos and colleagues5 found NM-MRI SN volumes significantly reduced in both idiopathic and LRRK2-PD (3 G2019S and 4 R1441G PD patients).engjournal article10.1002/mds.270831531-8257